Financial results

3Q 2022 consolidated results

Consolidated Income Statement Data
(Thousands of euro)	9M 2022	9M 2021
Total net sales	187,336	137,140
Gross profit	81,884	57,879
% on sales	44.7%	42.2%
Operating income	30,381	16,813
% on sales	16.2%	12.3%
EBITDA	41,365	25,504
% on sales	22.1%	18.6%
Income before taxes	12,785	17,818
% on sales	6.8%	13%
Group net income	3.594	10.383
% on sales	1.9%	7.6%

Consolidated Balance Sheet Data
(Thousands of euro)	September 30, 2022	December 31, 2021
Group shareholders' equity	269,077	253,520
Net financial position	53,076	74,801

STRONG SEQUENTIAL GROWTH IN REVENUES IN THE THREE QUARTERS OF 2022, THANKS TO BOTH THE INCREASE

IN VOLUMES AND THE FAVORABLE EFFECT OF THE DOLLAR

ORGANIC GROWTH OF 15% IN 3Q 2022 COMPARED TO 3Q 2021, MAINLY DRIVEN BY THE HIGH VACUUM AND THE

MEDICAL NITINOL DIVISIONS

EXCELLENT INDUSTRIAL PERFORMANCE, BUT CONSOLIDATED INCOME PENALIZED BY EXTRAORDINARY OPERATING

EXPENSES AND BY THE REDUCTION IN THE VALUE OF THE SECURITIES IN PORTFOLIO FOLLOWING THE INCREASE IN INTEREST RATES

Quarterly consolidated revenues equal to €67.1 million, up by 30.9% compared to €51.3 million in 3Q 2021
Consolidated gross profit equal to €28.6 million (42.7% of consolidated revenues) in 3Q 2022, compared to €22.5 million (43.9% of consolidated revenues) in 3Q 2021
Consolidated operating income equal to €10.1 million (€9.3 million in 3Q 2021) and consolidated EBITDA equal to €14 million in 3Q 2022 (€12.3 million in 3Q 2021), penalized by extraordinary operating expenses

of about €3.5 million
Consolidated income equal to €3.9 million in 3Q 2022 compared to €6.2 million in 3Q 2021, but the comparison is not significant due to the heavily penalizing effect of the increase in interest rates on the fair value of the securities portfolio as at September 30, 2022
Consolidated net financial position positive and stable, equal to €53.1 million as at September 30, 2022